drug_type
RELEVANT_DRUG
intervention_type
cellular therapy
drug_description
Autologous T lymphocytes genetically modified to express a chimeric antigen receptor that recognizes BCMA (TNFRSF17) on malignant plasma cells, activating T-cell cytotoxicity and cytokine release to kill myeloma cells.
nci_thesaurus_definition
NCI thesaurus definition not available.
drug_mesh_term
Chimeric Antigen Receptor T-Cell Therapy
drug_category
CAR T
drug_class
Cellular Therapy
drug_delivery_route
Intravenous
drug_mechanism_of_action
Autologous T lymphocytes are genetically engineered to express a chimeric antigen receptor that recognizes BCMA (TNFRSF17) on malignant plasma cells. CAR engagement activates T-cell signaling, inducing targeted cytotoxicity (perforin/granzyme) and cytokine release to kill myeloma cells.
drug_name
BCMA-directed CAR T cells
nct_id_drug_ref
NCT06126341